ALLO
Allogene Therapeutics, Inc.NASDAQHealthcare$2.48+4.84%ClosedMarket Cap: $604.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.96
P/S
0.00
EV/EBITDA
-3.67
DCF Value
$-0.12
FCF Yield
-23.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-57.1%
ROA
-45.9%
ROIC
-53.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-42.4M | $-38.8M | $-0.17 | — |
| FY 2025 | $0.00 | -Infinity% | $-206.9M | $-190.9M | $-0.87 | — |
| Q3 2025 | $0.00 | -Infinity% | $-44.9M | $-41.4M | $-0.19 | — |
| Q2 2025 | $0.00 | NaN% | $-56.8M | $-50.9M | $-0.23 | — |
| Q1 2025 | $0.00 | -Infinity% | $-65.2M | $-59.7M | $-0.28 | — |
| Q4 2024 | $0.00 | -Infinity% | $-60.5M | $-59.9M | $-0.28 | — |
| FY 2024 | $22.0K | 100.0% | $-273.2M | $-257.6M | $-1.32 | — |
| Q3 2024 | $0.00 | NaN% | $-71.8M | $-66.3M | $-0.32 | — |
| Q2 2024 | $0.00 | NaN% | $-71.4M | $-66.4M | $-0.35 | — |
| Q1 2024 | $22.0K | -16059.1% | $-69.5M | $-65.0M | $-0.38 | — |
| Q4 2023 | $-44.0K | 100.0% | $-85.2M | $-89.3M | $-0.51 | — |
| FY 2023 | $95.0K | 100.0% | $-327.7M | $-327.3M | $-2.09 | — |